Androgen-deprivation therapy-induced atherosclerosis in prostate cancer: Differences between GnRH-agonist and antagonist

Objectives: Cardiovascular disease (CVD) is one of the most common causes of mortality in prostate cancer patients. In prostate cancer treatment androgen deprivation therapy (ADT) is associated with weight gain and development of the metabolic syndrome. However, different modes of ADT can achieve castration. A post-hoc analysis of phase III trials suggests that GnRH-antagonists are associated with less cardiac events in men with pre-existing CVD during the first year of ADT. We investigated the effects of GnRH-agonist and GnRH-antagonist on the development of CVD in two mouse models.